Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GALECTIN THERAPEUTICS INC Director's Dealing 2020

Jan 14, 2020

33422_dirs_2020-01-13_31952699-f322-41e6-ba8c-8ed55465e83f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2020-01-09

Reporting Person: AMELIO GILBERT F (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-01-09 Stock option (right to buy) $2.86 A 40000 Acquired 2030-01-09 Common Stock (40000) Direct

Footnotes

F1: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F2: The options vest 100% on December 31, 2020.